Soy Isoflavones for Osteoporosis
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Soy Isoflavones in Osteoporosis grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.59
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
65%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.588
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-anal
Finding: Significant BMD improvements: lumbar spine MD=21.34 mg/cm² (p=0.001), femoral neck MD=28.88 mg/cm² (p<0.0001), distal radius MD=19.27 mg/cm² (p=0.006); genistein and ipriflavone most effective.
View on PubMed Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trial
Finding: Lumbar spine BMD MD=+0.76% (p=0.03); hip BMD MD=+0.22% (p=0.04); femoral neck BMD MD=+2.27% (p<0.001); osteoprotegerin increased (p<0.001); pyridinoline and C-telopeptides decreased significantly.
View on PubMed Effects of Soy Isoflavones on Biochemical Markers of Bone Metabolism in Postmenopausal Women: A Systematic Review an
Finding: OC increased 4.16% (p=0.49); BAP increased 5.50% (p=0.25); PYD decreased 12.09% (p=0.07); DPD decreased 7.48% (p=0.06) — all statistically non-significant; trend favorable but inconclusive.
View on PubMed The Role of Soy Isoflavones in the Prevention of Bone Loss in Postmenopausal Women: A Systematic Review with Meta-Ana
— See PubMed for details
View on PubMed Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial
Finding: 120 mg dose showed smaller reduction in whole-body BMD at 1y (p<0.03) and 2y (p<0.05), but no significant effect on regional BMD or BMD at common fracture sites (hip, spine).
View on PubMed Associations of dietary intakes of calcium, magnesium and soy isoflavones with osteoporotic fracture risk in postmenopa
Finding: Highest vs lowest soy isoflavone intake associated with HR 0.72 (95% CI 0.55–0.93) for fracture risk in women with prior fracture history; association modified by fracture history and time since menopause.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
L4b EU EFSA
Against
L4c UK NHS
Cautious
Complementary and alternative treatments, such as herbal remedies and compounded bioidentical ("natural") hormones, are not recommended for symptoms of the menopause or perimenopause. [...] Some complementary and alternative therapies can also interact with other medicines and cause side effects. [nhs.uk/conditions/menopause/treatment/] | NICE NG23 rec.1.4.7: "Explain to people that there is so… source↗
L4d TW TFDA / 衛福部
Cautious
使用原料『大豆萃取物』之有容器或包裝食品應標示警語：「不建議兒童、少年、孕婦、哺乳期婦女、婦科腫瘤患者或有其家族病史者食用」及「異黃酮(Isoflavones)每日食用限量為50毫克以下」字樣，並應於產品容器或外包裝標示該產品依每日建議食用量之異黃酮含量。 source↗
L5b Mayo Clinic
Cautious
Data available from human studies on the effect of isoflavones on osteoporosis are limited, and additional studies are needed to support a role in osteoporosis prevention. source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Not addressed